Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BPTF | Q12830 | 1/20 | 0.66 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16423974 | 1.00 | BPTF (0.66) | BPTFCHRNB2CHRNA4CHRNA7ALDH1A1 | |
| SCHEMBL27031079 | 1.00 | BPTF (0.66) | BPTFCHRNB2CHRNA4CHRNA7ALDH1A1 | |
| Hydrochloric Acid SCHEMBL17134678 | 0.98 | BPTF (0.63) | BPTFCHRNB2CHRNA4CHRNA7ALDH1A1 | |
| SCHEMBL22728546 | 0.83 | BPTF (0.50) | BPTFCHRNB2CHRNA4CHRNA7 | |
| SCHEMBL29732584 | 0.83 | BPTF (0.50) | BPTFCHRNB2CHRNA4CHRNA7 | |
| SCHEMBL13783969 | 0.81 | ALDH1A1 (0.47) | BPTFALDH1A1LMNAMAPTMAPK1 | |
| SCHEMBL24495224 | 0.80 | BPTF (0.66) | BPTFCHRNB2CHRNA4CHRNA7 | |
| SCHEMBL22015317 | 0.80 | BPTF (0.66) | BPTFCHRNB2CHRNA4CHRNA7 | |
| SCHEMBL20510583 | 0.80 | BPTF (0.66) | BPTFCHRNB2CHRNA4CHRNA7 | |
| SCHEMBL22523821 | 0.80 | BPTF (0.66) | BPTFCHRNB2CHRNA4CHRNA7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4472963-A1 | DGK TARGETING COMPOUNDS AND USES THEREOF | Arvinas Operations, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| CN-113365984-B | LOX inhibitors | 癌症研究协会皇家癌症医院 | 2024-10-15 | — | — | CN | disclosed |
| WO-2023150186-A1 | DGK TARGETING COMPOUNDS AND USES THEREOF | ARVINAS OPERATIONS, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| US-20220017516-A1 | LOX INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2022-01-20 | — | — | US | disclosed |
| WO-2020099886-A1 | LOX INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017516-A1 | LOX INHIBITORS | LOXL1, LOX, LOXL2 | BPTF 3130/4885CHRNB2 3882/4885CHRNA4 4539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.